Prof. Kui Liu | Breast Cancer | Best Researcher Award

Prof. Kui Liu | Breast Cancer | Best Researcher Award

Zibo Central Hospital | China

AUTHOR PROFILE

Scopus

KUI LIU, Ph.D. – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Kui Liu embarked on a robust academic journey in clinical and diagnostic sciences:

  • 2002-2005: Completed a degree in Clinical Laboratory Medicine from Linyi Medical College, China.
  • 2012-2015: Pursued a master’s degree in Clinical Laboratory Diagnostics at Jiangsu University, Zhenjiang, China.
  • 2016-2020: Earned a Ph.D. in Immunology from Southeast University, Nanjing, China, contributing significantly to the field with innovative research in immune responses and diagnostics.

💼 PROFESSIONAL ENDEAVORS

Kui Liu has accumulated extensive clinical and technical experience over nearly two decades:

  • 2020-Present: Associate Chief Technician at the Center of Translational Medicine, Zibo Central Hospital, where he plays a key role in integrating research with clinical applications.
  • 2015-2016: Worked as a Docimaster at the Blood Bank of the First Hospital of Zibo, focusing on blood storage and safety protocols.
  • 2008-2012: Served as a Docimaster at the same institution, ensuring high-quality diagnostic practices.
  • 2005-2008: Began his career as a Docimaster in the Laboratory Department, excelling in clinical diagnostics.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER

Kui Liu’s research is centered on advancing the fields of immunology and clinical diagnostics, with a focus on:

  • The study of immune responses in various pathological conditions.
  • Development of innovative diagnostic tools and techniques.
  • Translation of scientific research into clinical solutions.

His work on immune mechanisms and diagnostic technologies has led to groundbreaking advancements in translational medicine.

💡 FUNDING AND RESEARCH IMPACT

Kui Liu has been a driving force behind several high-impact research projects, securing prestigious grants to fund cutting-edge studies:

  • Grant no. 81602330: Principal Investigator for the National Natural Science Foundation of China (2017-2019), focusing on immunological research.
  • Grant no. 81972002: Co-Investigator for the National Natural Science Foundation of China (2019-2022), contributing to collaborative advancements in the field.
  • Grant no. J18KA299: Co-Investigator in the Shandong Province Higher Educational Science and Technology Program (2019-2021).
  • Grant no. ZR2015PH056: Co-Investigator for the Natural Science Foundation of Shandong Province (2015-2016).
  • Grant no. CXLX13_689: Principal Investigator for the Innovation Project of Cultivating Graduates of Jiangsu Province (2013-2015).

🌍 IMPACT AND INFLUENCE

  • Innovator in Translational Medicine: Kui Liu has bridged the gap between laboratory research and clinical application, enhancing diagnostic capabilities in immunology.
  • National and Regional Contributions: Through leadership in provincial and national projects, he has elevated the standards of diagnostic medicine across China.
  • Collaboration and Mentorship: Actively fosters collaborations and guides aspiring researchers, contributing to the growth of the next generation of medical scientists.

📚 ACADEMIC CITES AND RECOGNITION

Kui Liu has received widespread recognition for his contributions, reflected in numerous citations and acknowledgments in scientific journals. His findings have influenced medical practices and inspired continued exploration in immunology.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Kui Liu’s career is a testament to his commitment to advancing medical science. His future endeavors include:

  • Leading innovative studies in immunological diagnostics.
  • Expanding the applications of translational medicine.
  • Continuing to inspire young researchers through mentorship and collaboration.

🌟CONCLUSION 

Dr. Kui Liu’s remarkable journey from foundational clinical studies to advanced immunological research exemplifies a career dedicated to innovation, excellence, and impact. His contributions to translational medicine and diagnostics have not only advanced scientific understanding but also improved clinical practices, particularly in immunology.

 

📊🔬NOTABLE PUBLICATION:
    1. Title: LncRNA DANCR-miR-758-3p-PAX6 Molecular Network Regulates Apoptosis and Autophagy of Breast Cancer Cells
      • Authors: Zhang, X.H., Li, B.F., Ding, J., Ma, F.X., Wu, X.Y.
      • Journal: Cancer Management and Research
      • Year: 2020

    1. Title: LncRNA PVT1 Regulates Gallbladder Cancer Progression through miR-30d-5p
      • Authors: Liu, K., Xu, Q.
      • Journal: Journal of Biological Regulators and Homeostatic Agents
      • Year: 2020

    1. Title: TIPE1 Inhibits Osteosarcoma Tumorigenesis and Progression by Regulating PRMT1 Mediated STAT3 Arginine Methylation
      • Authors: Yang, M., Zhang, Y., Liu, G., Liu, Q., Zhao, P.
      • Journal: Cell Death and Disease
      • Year: 2022

    1. Title: CircRNA hsa_circ_0008500 Acts as a miR-1301-3p Sponge to Promote Osteoblast Mineralization by Upregulating PADI4
      • Authors: Zhai, Q., Zhao, Y., Wang, L., Li, T., Wang, L.
      • Journal: Frontiers in Cell and Developmental Biology
      • Year: 2020

    1. Title: miR-369-3p Inhibits Tumorigenesis of Hepatocellular Carcinoma by Binding to PAX6
      • Authors: Xu, Q., Liu, K.
      • Journal: Journal of Biological Regulators and Homeostatic Agents
      • Year: 2020

Prof. Linghua Li | Cancer Science | Best Researcher Award

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

👩‍⚕️Biography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑‍⚕️ Internal and Infectious Diseases

📚Academic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

🔬Research Impact

🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

📊🔬NOTABLE PUBLICATION:
  • Utilizing Protein–Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023